- Time:
The spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) ranges from simple lipid accumulation in the human liver, to steatohepatitis with inflammation, fibrosis, cirrhosis, and even the development of hepatocellular carcinoma.
Globally, MASLD affects up to 25 percent of the population. Despite the magnitude of the problem, there are still no efficacious therapies capable of curing the various iterations of the disease. This is mainly due to the complexity of the disease pathogenesis and the lack of predictive pre-clinical models.
In this GEN webinar, Prof. Jeremy Tomlinson will discuss the pathogenesis of MASLD, share examples from recent research that highlight current progress and advancements in the clinic, and explore the importance of developing efficient pre-clinical models to identify and characterize novel cellular targets associated with disease progression. During the webinar, you will learn about DefiniGEN’s highly characterized iPSC-derived hepatocytes (Opti-HEP), and how these cells can recapitulate the disease phenotype in vitro, offering an optimal pre-clinical platform for the large-scale screening of novel therapeutics against MASLD.
A live Q&A session followed the presentation, offering you a chance to pose questions to our expert panelists.
Professor of Metabolic Endocrinology
University of Oxford
Head of Research and Development
DefiniGEN
Webinar produced with support from:
